Anti-cancer combinations

Details Anti-cancer combinations Anti-cancer combinations

2011-01-04

2011-01-04

Anderson, James D (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S457000

Reexamination Certificate

active

07863322

ABSTRACT:
The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

REFERENCES:
patent: 3678077 (1972-07-01), Nakanishi et al.
patent: 4602034 (1986-07-01), Briet et al.
patent: 4704355 (1987-11-01), Bernstein et al.
patent: 5126129 (1992-06-01), Wiltrout et al.
patent: 5281620 (1994-01-01), Denny et al.
patent: 5464826 (1995-11-01), Grindey et al.
patent: 5620875 (1997-04-01), Hoffman et al.
patent: 5817684 (1998-10-01), Fleisch et al.
patent: 5863904 (1999-01-01), Nabel et al.
patent: 5910505 (1999-06-01), Fleisch et al.
patent: 6174873 (2001-01-01), Wrenn
patent: 6194454 (2001-02-01), Dow
patent: 6667337 (2003-12-01), Wilson
patent: 6806257 (2004-10-01), Lee et al.
patent: 2001/0027210 (2001-10-01), Wilson
patent: 2001/0041713 (2001-11-01), Waldstreicher et al.
patent: 2003/0003092 (2003-01-01), Krissansen et al.
patent: 2004/0087611 (2004-05-01), Baguley et al.
patent: 2005/0131059 (2005-06-01), Wang et al.
patent: 2006/0009505 (2006-01-01), Baguley et al.
patent: 2007/0082937 (2007-04-01), Baguley et al.
patent: 2008/0070847 (2008-03-01), Wilson et al.
patent: 2008/0070848 (2008-03-01), Wilson et al.
patent: 2008/0070849 (2008-03-01), Wilson et al.
patent: 2008/0070886 (2008-03-01), Wilson et al.
patent: 2015265 (1970-10-01), None
patent: 19721211 (1998-11-01), None
patent: 0278176 (1988-08-01), None
patent: 0326149 (1989-08-01), None
patent: 0385467 (1990-09-01), None
patent: 0488718 (1992-06-01), None
patent: 0551200 (1993-07-01), None
patent: 0 584 001 (1994-02-01), None
patent: 0743 064 (1996-11-01), None
patent: 0 584 001 (1997-05-01), None
patent: 0121285.1 (2001-09-01), None
patent: 0206839.3 (2002-05-01), None
patent: 0225508.1 (2002-11-01), None
patent: 0604114.9 (2006-03-01), None
patent: 0157387.7 (2006-08-01), None
patent: 0517386.9 (2006-08-01), None
patent: 09040690 (1997-02-01), None
patent: 2001247459 (2001-09-01), None
patent: 336259 (1999-06-01), None
patent: 506060 (2000-07-01), None
patent: 99121332 (2001-07-01), None
patent: 2195946 (2003-01-01), None
patent: WO 91/04014 (1991-04-01), None
patent: WO94/23753 (1994-10-01), None
patent: WO 95/09621 (1995-04-01), None
patent: WO 96/32418 (1996-10-01), None
patent: WO 96/36347 (1996-11-01), None
patent: WO 97/04761 (1997-02-01), None
patent: WO 97/34482 (1997-09-01), None
patent: WO 98/25600 (1998-06-01), None
patent: WO 98/25615 (1998-06-01), None
patent: WO 98/25616 (1998-06-01), None
patent: WO 98/42332 (1998-10-01), None
patent: WO 98/42334 (1998-10-01), None
patent: WO 98/42335 (1998-10-01), None
patent: WO 98/42336 (1998-10-01), None
patent: WO 98/42337 (1998-10-01), None
patent: WO 98/42345 (1998-10-01), None
patent: WO 98/42346 (1998-10-01), None
patent: WO 98/42650 (1998-10-01), None
patent: WO 00/10600 (2000-03-01), None
patent: WO 00/10600 (2000-03-01), None
patent: WO 00/15176 (2000-03-01), None
patent: WO 00/16798 (2000-03-01), None
patent: WO 00/48591 (2000-08-01), None
patent: WO 00/76497 (2000-12-01), None
patent: WO 01/34135 (2001-05-01), None
patent: WO 01/34137 (2001-05-01), None
patent: WO 01/34197 (2001-05-01), None
patent: WO 01/34198 (2001-05-01), None
patent: WO02/09700 (2002-02-01), None
patent: WO 03/080044 (2003-10-01), None
patent: WO 2004/039363 (2004-05-01), None
patent: WO 2005/027974 (2005-03-01), None
patent: WO 2007/023302 (2007-03-01), None
patent: WO 2007/023307 (2007-03-01), None
patent: WO 2009/053681 (2009-04-01), None
Cliffe et al., International Journal of Radiation Oncology Biology Physics, (1994) vol. 29, No. 2, pp. 373-377.
Zhou et al., British Journal of Clinical Pharmacology, (Aug. 2001), vol. 52, No. 2, pp. 129-136.
Siemann et al., Proceedings of the American Association for Cancer Research Annual Meeting, (Mar. 2000), No. 41, p. 525.
Goodman &Gilman's, The Pharmacological Basis of Therapeutics, Ninth Edition, (1996), Calabresi et al., Section X, Chemotherapy of Neoplastic Diseases, pp. 1225-1229.
Pruijn et al. Mechanisms of enhancement of the antitumor activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol., 1997, col. 39, pp. 541-546.
van Moorsel et al. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochemical Pharmacology, 1999, vol. 57, pp. 407-415.
Peters et al. Pharmacology & Therapeutics, 2000, vol. 87, pp. 227-253.
Hill, et al., “Anti-Vascular Approaches to Solid Tumour Therapy: Evaluation of Vinblastine and Flavone Acetic Acid”, International Journal of Cancer (1995), V. 63, No. 1, pp. 119-123.
Rewcastle, et al., “Potential Antitumor Agents. 61. Structure-Activity Relationships for in Vivo Colon 38 Activity Among Disubstituted 9-Oxo-9H-xanthene-4-acetic Acids”, Journal of Medicinal Chemistry (1991), V. 34, No. 1, pp. 217-222.
Siemann, et al., “Vascular Targeting Agents Enhance Chemotherapeutic Agent Activities in Solid Tumor Therapy”, International Journal of Cancer (2002), V. 99, pp. 1-6.
The International Search Report (PCT/GB02/04025).
Showalter & Hollis; “Potential Antitumor Agents. 61. Structure-Activity Relationships for In Vivo Colon 38 Activity Among Disubstituted 9-Oxo-9H-xanthene-4-acetic acids”; 1991;Chemtracts: Org. Chem. 4(2): 168-171.
Shoemaker, et al.; “Pleiotropic Resistance and Drug Development”; 1986;Progress Clin. Biol. Res.; 223: 143-149.
Van der Auwera, et al.; “Conformational Features of Four Model Tripeptides having Piv-Pro-MeXaa-Nme2Sequences”; 1988;Bull. Soc. Chim. Belg.; 97(3): 199-207.
Ching & Baguley; “The Anti-Tumour and Immune-Modulatory Activities of Flavone Acetic and Xanthone Acetic Acids”; 1990;N.P. Das(ed.),flavanoids in Biology and Medicine III. Proceedings of the 3rdInternational Symposium on Flavonoids in Biology and Medicine, Singapore; National University of Singapore; 381-391.
Bibby, et al.; “Reduction of Tumor Blood Flow by Flavone Acetic Acid: A Possible Component of Therapy”; 1989;J. Natl. Cancer Inst.; 81: 216-220.
Zhou, et al.; “Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes”; 2001;Br. J. Clin. Pharmacol.; 52: 129-136.
Rewcastle, et al.; “Potential Antitumor Agents. 61. Structure-Activity Relationships for In Vivo Colon 38 Activity Among Disubstituted 9-Oxo-9H-xanthene-4-acetic acids”; 1991;J. Med. Chem.; 34: 217-222.
Hill, et al., “Anti-Vascular Approaches to Solid Tumour Therapy: Evaluation of Vinblastine and Flavone Acetic Acid”, International Journal of Cancer (1995), V. 63, No. 1, pp. 119-123.
Wilson; “Combination of the Antivascular Agent DMXAA with Radiation and Chemotherapy”; 2000;Internation Journal of Radiation Oncology, Biology and Physics; 46(3): 706.
Kanwar, et al.; “Taking lessons form dendritic cells: Multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity”;Gene Therapy; 1999; 6: 1835-1844.
Kanwar, et al.; “Vascular Attack by 5-6-Dimethylxanthenone-4-acetic Acid Combined with B7.1 (CD80)-mediated Immunotherapy Overcomes Immune Resistance and Leads to the Eradication of Large Tumors and Multiple Tumor Foci1”;Cancer Res

Affiliated with

Also associated with

Rating

Anti-cancer combinations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-cancer combinations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer combinations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2646271